← Back to Search

Anticoagulant

Ticagrelor first for Heart Attack (DEFINE CCS Trial)

Phase 4
Recruiting
Research Sponsored by Nova Scotia Health Authority
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 7 days
Awards & highlights

Summary

This trial will compare two drug treatments in heart attack survivors to see which one has fewer risks of bleeding/clotting. Both treatments are already approved for heart attack patients.

Eligible Conditions
  • Heart Attack
  • Blood Clot

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~7 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 7 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Bleeding time
Secondary study objectives
Differential effects on fibrin clot lysis time
Differential effects on inflammatory markers (white cell count and CRP)

Trial Design

2Treatment groups
Active Control
Group I: Ticagrelor firstActive Control2 Interventions
Patients will be treated with ticagrelor 60 mg twice a day for one week then on Day 21, will be treated with rivaroxaban 2.5 mg twice a day for one week.
Group II: Rivaroxaban firstActive Control2 Interventions
Patients will be treated with rivaroxaban 2.5 mg twice a day for one week then on Day 21, will be treated with ticagrelor 60 mg twice a day for one week.

Find a Location

Who is running the clinical trial?

Nova Scotia Health AuthorityLead Sponsor
286 Previous Clinical Trials
94,234 Total Patients Enrolled
~8 spots leftby Sep 2025